{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-082341","form_type":"8-K","ticker":"ANVS","cik":"0001477845","company_name":"Annovis Bio, Inc.","filed_at":"2026-07-10T01:06:20+00:00","discovered_at":"2026-07-10T10:05:00.271139+00:00","generated_at":"2026-07-10T10:05:25.843307+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Annovis Bio completes enrollment of 850 patients in pivotal Phase 3 AD trial of buntanetap","bullets":["Enrolled 850 pTau217-confirmed early AD patients across 83 US sites, exceeding original projections.","Symptomatic top-line data expected Q1 2027; disease-modifying data expected Q1 2028.","Company plans two NDA submissions to FDA after each respective data readout.","Trial is randomized, placebo-controlled, double-blind with daily oral buntanetap 30mg.","Last patient completes 6-month treatment in January 2027; study on track."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-082341","json":"https://secwatch.observer/filing/0001104659-26-082341.json","markdown":"https://secwatch.observer/filing/0001104659-26-082341.md","text":"https://secwatch.observer/filing/0001104659-26-082341.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1477845/000110465926082341/0001104659-26-082341-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1477845/000110465926082341/tm2620172d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-10T10:05:25.843307+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}